Therefore, personalizing PAH treatment in this context could be a valid approach; however, further preclinical and clinical research is essential to fully understand the implications of SIRT1 as a potential therapeutic target, independent of body mass. The gene discussed is SIRT1; the disease is pulmonary arterial hypertension.